Compare ELAN & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELAN | CYTK |
|---|---|---|
| Founded | 1954 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 10.7B |
| IPO Year | 2018 | 2004 |
| Metric | ELAN | CYTK |
|---|---|---|
| Price | $25.79 | $80.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 19 |
| Target Price | $27.89 | ★ $89.26 |
| AVG Volume (30 Days) | ★ 3.8M | 2.3M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $4,715,000,000.00 | $13,368,000.00 |
| Revenue This Year | $8.21 | $7.37 |
| Revenue Next Year | $5.31 | $310.19 |
| P/E Ratio | $236.14 | ★ N/A |
| Revenue Growth | ★ 6.22 | N/A |
| 52 Week Low | $13.39 | $32.89 |
| 52 Week High | $27.72 | $88.31 |
| Indicator | ELAN | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 62.30 | 49.47 |
| Support Level | $23.56 | $59.07 |
| Resistance Level | $26.26 | $88.31 |
| Average True Range (ATR) | 0.87 | 2.98 |
| MACD | 0.09 | -0.86 |
| Stochastic Oscillator | 78.83 | 21.81 |
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.